Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage. We studied the expression of DDR, its relationship with standard treatment re...
Main Authors: | Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Bryan W. Day, Brett W. Stringer, Paul A. Tooney |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/7/1215 |
Similar Items
-
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01) -
Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
by: Celina Bihan, et al.
Published: (2012-09-01) -
Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01) -
Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01) -
Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
by: Rodrigo Ramella Munhoz, et al.
Published: (2013-08-01)